Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.
Pharmacopsychiatry. 2010 Mar;43(2):50-7. doi: 10.1055/s-0029-1239539. Epub 2009 Dec 10.
The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia.
This was an investigator-initiated, open label eight-week trial evaluating 56 inpatients with the DSM-IV diagnosis of schizophrenia. Efficacy was assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and tolerability was assessed each week using the Udvalg for Klinske Undersogelser side effect rating scale (UKU). Cognitive function was assessed at baseline, week 4 and week 8.
Aripiprazole showed significant improvement in PANSS total score and all subscores between baseline and endpoint visit. The substance was very well tolerated. Patients improved significantly in verbal memory, reaction time and reaction quality/attention from baseline to week eight. Furthermore, mean z-values of individual cognitive domains summarized in a global cognitive index improved significantly from baseline to week eight.
Our results suggest that aripiprazole provides a valuable treatment option for patients with schizophrenia.
本研究旨在评估阿立哌唑对精神分裂症住院患者的认知影响。
这是一项由研究者发起的、为期八周的开放性标签试验，评估了 56 名符合 DSM-IV 精神分裂症诊断标准的住院患者。使用阳性和阴性症状量表（PANSS）每周评估疗效，使用 Udvalg for Klinske Undersogelser 副作用评定量表（UKU）每周评估耐受性。在基线、第 4 周和第 8 周评估认知功能。
阿立哌唑在 PANSS 总分和所有子量表上均显示出从基线到终点访视的显著改善。该物质具有很好的耐受性。患者的言语记忆、反应时间和反应质量/注意力从基线到第 8 周显著提高。此外，个体认知域的平均 z 值汇总在一个整体认知指数中，从基线到第 8 周显著提高。
我们的结果表明，阿立哌唑为精神分裂症患者提供了一种有价值的治疗选择。
